A Randomized,Double‐Blind,Placebo‐Controlled Trial of Naltrexone in the Treatment of Concurrent Alcohol Use Disorder and Pathological Gambling |
| |
| Authors: | Tony Toneatto PhD Bruna Brands PhD Peter Selby MBBS |
| |
| Affiliation: | 1. Clinical Research Department, Center for Addiction and Mental Health, Toronto, Ontario, Canada;2. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada;3. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada;4. Office of Research and Surveillance, Drug Strategy and Controlled Substances Programme, Health Canada, Ontario, Canada;5. Public Health and Regulatory Policy Section, Center for Addiction and Mental Health, Toronto, Ontario, Canada;6. Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada;7. Addictions Program, Center for Addiction and Mental Health, Toronto, Ontario, Canada;8. Nicotine Dependence Clinic, Center for Addiction and Mental Health, Toronto, Ontario, Canada;9. Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada |
| |
| Abstract: | The efficacy of naltrexone as a treatment for concurrent alcohol abuse or dependence and pathological gambling was evaluated in a randomized, double‐blind, placebo‐controlled trial. Fifty‐two, mostly male, subjects were recruited from the community and received 11 weeks of medication during which cognitive‐behavioral counseling was also provided. No significant group differences were found on any alcohol or gambling variable (ie, frequency, quantity, expenditures) at post‐treatment or at the one year follow‐up. However, a strong time effect was found suggesting that treatment, in general, was effective. The use of naltrexone to treat concurrent alcohol use and gambling problems was not supported. |
| |
| Keywords: | |
|
|
